Total Funding
51
Total FundingSeries B raised
Growth Score
pts
Heat Score
4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Aerami Therapeutics focuses on developing novel inhaled therapies for the treatment of chronic diseases.
Darlene Deptula-Hicks: Board Member & Audit Committee ChairPast Role: Pieris Pharmaceuticals, Sr. Vice President & Chief Financal Officer- Barry Deutsch: CFOPast Role: Xeris Biopharma, Chief Financial Officer
About the Company
Aerami Therapeutics focuses on developing novel inhaled therapies for the treatment of chronic diseases. It features a proprietary, smart, handheld soft mist device that allows convenient and confident delivery of insulin into a patient's lungs in just a few breaths yielding high lung deposition and distribution.
It was founded in 2010 and
headquartered in Durham, North Carolina.
